Subtopic Deep Dive
Antiviral Therapy for Herpes Simplex Virus
Research Guide
What is Antiviral Therapy for Herpes Simplex Virus?
Antiviral therapy for herpes simplex virus (HSV) uses nucleoside analogs like acyclovir, valacyclovir, and famciclovir to inhibit HSV-1 and HSV-2 replication in treating infections including genital herpes, neonatal disease, and encephalitis.
Acyclovir established efficacy in neonatal HSV infections (Kimberlin et al., 2001, 572 citations) and natural history studies (Kimberlin et al., 2001, 505 citations). PCR diagnostics enable rapid detection critical for therapy initiation (Lakeman and Whitley, 1995, 675 citations; Mackay, 2002, 1285 citations). Suppressive therapy reduces transmission, with cesarean delivery lowering neonatal rates (Brown et al., 2003, 670 citations). Over 10 key papers span diagnostics to management.
Why It Matters
Acyclovir high-dose regimens improved neonatal HSV survival from 30% to over 80% (Kimberlin et al., 2001, 572 citations). Suppressive valacyclovir prevents recurrent genital outbreaks and HIV acquisition risk in HSV-2 prevalent populations (Looker et al., 2015, 520 citations). PCR-guided therapy confirms HSE diagnosis noninvasively, enabling timely acyclovir administration (Lakeman and Whitley, 1995, 675 citations). These therapies reduce transmission in organ transplant recipients (Fishman, 2017, 753 citations) and manage zoster-like complications (Dworkin et al., 2006, 827 citations).
Key Research Challenges
Antiviral Resistance Emergence
Prolonged acyclovir use in immunocompromised patients leads to thymidine kinase mutations causing resistance in up to 5% of cases. Neonatal and transplant settings amplify this risk (Fishman, 2017). Alternative therapies like foscarnet remain toxic.
Neonatal Transmission Prevention
Maternal HSV shedding near delivery causes 1-2% transmission despite antivirals, mitigated partially by cesarean (Brown et al., 2003, 670 citations). Serologic screening gaps persist in low-resource areas. Invasive monitoring increases risk.
Diagnostic-Therapy Delays
HSE requires rapid PCR for CSF to start acyclovir before biopsy (Lakeman and Whitley, 1995, 675 citations). Real-time PCR sensitivity varies by virology lab standards (Mackay, 2002, 1285 citations). Delays worsen encephalitis outcomes.
Essential Papers
Real-time PCR in virology
Ian M Mackay · 2002 · Nucleic Acids Research · 1.3K citations
The use of the polymerase chain reaction (PCR) in molecular diagnostics has increased to the point where it is now accepted as the gold standard for detecting nucleic acids from a number of origins...
Recommendations for the Management of Herpes Zoster
Robert H. Dworkin, Robert W. Johnson, Judith Breuer et al. · 2006 · Clinical Infectious Diseases · 827 citations
The objective of this article is to provide evidence-based recommendations for the management of patients with herpes zoster (HZ) that take into account clinical efficacy, adverse effects, impact o...
Infection in Organ Transplantation
J. A. Fishman · 2017 · American Journal of Transplantation · 753 citations
Diagnosis of Herpes Simplex Encephalitis: Application of Polymerase Chain Reaction to Cerebrospinal Fluid from Brain-Biopsied Patients and Correlation with Disease
Fred D. Lakeman, Richard J. Whitley · 1995 · The Journal of Infectious Diseases · 675 citations
Isolation of herpes simplex virus (HSV) from brain tissue after biopsy has been considered the reference standard for the diagnosis of herpes simplex encephalitis (HSE). During the evaluation of an...
Effect of Serologic Status and Cesarean Delivery on Transmission Rates of Herpes Simplex Virus From Mother to Infant
Zane A. Brown, Anna Wald, Rhoda Ashley Morrow et al. · 2003 · JAMA · 670 citations
Neonatal HSV infection rates can be reduced by preventing maternal acquisition of genital HSV-1 and HSV-2 infection near term. It can also be reduced by cesarean delivery and limiting the use of in...
Host defense, viruses and apoptosis
Glen N. Barber · 2001 · Cell Death and Differentiation · 586 citations
Safety and Efficacy of High-Dose Intravenous Acyclovir in the Management of Neonatal Herpes Simplex Virus Infections
David W. Kimberlin, Chin‐Yu Lin, Richard F. Jacobs et al. · 2001 · PEDIATRICS · 572 citations
Objective. The objective of this investigation was to establish the safety of high-dose (HD) acyclovir for the treatment of neonatal herpes simplex virus (HSV) disease. In addition, an estimate of ...
Reading Guide
Foundational Papers
Start with Lakeman and Whitley (1995, 675 citations) for PCR diagnosis enabling therapy; Kimberlin et al. (2001, 572+505 citations) for neonatal acyclovir efficacy; Mackay (2002, 1285 citations) for real-time PCR virology standard.
Recent Advances
Fishman (2017, 753 citations) on transplant infections; Looker et al. (2015, 520 citations) on HSV-2 global burden driving suppressive needs; Whitley (2006, 529 citations) on adult HSE management.
Core Methods
Real-time PCR (Mackay, 2002); high-dose acyclovir (Kimberlin et al., 2001); serology/cesarean for neonatal prevention (Brown et al., 2003); suppression dosing.
How PapersFlow Helps You Research Antiviral Therapy for Herpes Simplex Virus
Discover & Search
Research Agent uses searchPapers('acyclovir neonatal HSV') to retrieve Kimberlin et al. (2001, 572 citations), then citationGraph reveals 500+ citing works on resistance; exaSearch('HSV suppressive therapy valacyclovir') finds Looker et al. (2015); findSimilarPapers expands to Fishman (2017) for transplant contexts.
Analyze & Verify
Analysis Agent applies readPaperContent on Kimberlin et al. (2001) to extract survival rates (54% to 83%), verifies via CoVe against Brown et al. (2003); runPythonAnalysis parses CSV of 10 papers' citation trends with pandas, confirming acyclovir dominance; GRADE grades evidence as high for neonatal dosing.
Synthesize & Write
Synthesis Agent detects gaps in resistance alternatives post-Kimberlin et al. (2001); Writing Agent uses latexEditText for therapy protocols, latexSyncCitations integrates 20 papers, latexCompile generates review PDF; exportMermaid diagrams PCR workflow from Mackay (2002) to HSE therapy.
Use Cases
"Analyze survival rates in neonatal HSV acyclovir trials over time"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas plots Kimberlin 2001 vs. 2001 natural history) → matplotlib survival curve output.
"Draft LaTeX review on HSV encephalitis antiviral management"
Synthesis Agent → gap detection → Writing Agent → latexEditText (protocols) → latexSyncCitations (Lakeman/Whitley 1995) → latexCompile → PDF with Whitley (2006) diagram.
"Find code for real-time PCR HSV quantification from papers"
Research Agent → searchPapers('real-time PCR HSV Mackay') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → Python scripts for Ct value analysis from Mackay (2002).
Automated Workflows
Deep Research workflow scans 50+ HSV papers via citationGraph from Kimberlin et al. (2001), outputs structured report with GRADE scores on acyclovir efficacy. DeepScan applies 7-step CoVe to verify resistance claims against Fishman (2017), flagging contradictions. Theorizer generates hypotheses on valacyclovir dosing from Looker et al. (2015) prevalence data.
Frequently Asked Questions
What defines antiviral therapy for HSV?
Nucleoside analogs acyclovir, valacyclovir, famciclovir inhibit HSV DNA polymerase, treating genital, neonatal, and CNS infections (Kimberlin et al., 2001).
What are main methods in HSV antiviral therapy?
High-dose IV acyclovir for neonates (60 mg/kg/day, Kimberlin et al., 2001, 572 citations); oral valacyclovir suppression; PCR diagnostics guide initiation (Mackay, 2002).
What are key papers on HSV therapy?
Kimberlin et al. (2001, 572 citations) on neonatal acyclovir safety; Lakeman and Whitley (1995, 675 citations) on PCR for HSE; Brown et al. (2003, 670 citations) on transmission prevention.
What open problems exist in HSV antivirals?
Antiviral resistance in transplants (Fishman, 2017); optimizing suppression to curb HSV-2 burden (Looker et al., 2015); novel agents beyond nucleosides.
Research Herpesvirus Infections and Treatments with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Antiviral Therapy for Herpes Simplex Virus with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.